Raed Al Rajabi, MD

Dr. Al-Rajabi is a Professor of medicine in the division of medical oncology at the University of Kansas Medical Center and leads the GI medical oncology group.

Dr. Al-Rajabi received his medical degree from the University of Jordan and proceeded to complete his internal medicine residency and chief residency at St. Vincent's Charity Hospital/Case Western Reserve University in Cleveland Ohio. He completed his hematology-oncology fellowship at the University of Texas health science center San Antonio. His research interests include clinical and translational research in gastrointestinal malignancies.

In 2013 moved to Kansas he worked at both the Kansas City VA and the University of Kansas Medical Center. Developed a multidisciplinary liver cancer clinic to serve affected veterans. In 2016 transitioned full-time to the University of Kansas Cancer Center to lead the GI oncology group and expanding the GI research program.

Dr. Al-Rajabi also serves as the advanced clinical informatics director at the University of Kansas Cancer Center.

Dr. Al-Rajabi cultures the GI disease working group. He is very actively involved in clinical and translational GI malignancy research. With a special interest in liver cancer, biliary cancers, neuroendocrine cancers, pancreatic cancers, colorectal cancer and anal cancers. Dr. Al-Rajabi has served as PI on several therapeutic trials in the GI oncology.

Controversies in Rectal Cancer Treatment and Management

Doublecortin like kinase 1 is a therapeutic target in squamous cell carcinoma

Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.

Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open- label, phase 2 study

Similar response rates and survival with PARPi treatments for patients harboring somatic versus germline BRCA mutations: A meta-analysis and systematic review

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202). NCT02924376

Maintenance therapy with avelumab versus continuation of first line chemotherapy in subjects with unresectable locally advanced or metastatic adenocarcinoma of the stomach. NCT02625623

Ramucirumab Doses in combination with paclitaxel in second-line metastatic or locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma. NCT02514551

Ruxolitinib or Placebo in Combination with Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy

Single agent Pembrolizumab vs single agent docetaxel paclitaxel or irinotecan in subjects with advanced metastatic adenocarcinoma. NCT02564263

Single agent Pembrolizumab vs single agent docetaxel paclitaxel or irinotecan in subjects with advanced metastatic adenocarcinoma.

Study in patients with esophageal cancer refractory or intolerant to combination therapy with fluoropyrimidine and platinum based drugs. NCT03298451

Study of Gemcitabine Abraxane Plus Placebo

Study of Pembrolizumab vs best supportive care as second line therapy in subjects with previously systemically treated advanced Hepatocellular Carcinoma. NCT03062358